TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Long Term Minor Sibling Donor Well-Being

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. sibling of an allogeneic cell therapy transplant patient -- the persons receiving allogeneic transplant may have either an acquired or congenital disease. Acquired diseases include acute lymphoblastic leukemia, acute myelogenous leukemia, severe aplastic anemia, hemoglobinopathies, and lymphomas.Congenital diseases are comprised of hemoglobinopathies and glycogen/lysosomal disorders. Transplant is being considered after failure to respond to traditional therapies or due to the nature of the disease.~2. 5 to 19 years of age~3. speaks English or Spanish~4. one parent or legal guardian willing to participate~5. mentally able to render a valid assessment~6. donor is harvested at this institution~7. donors will participate in the standard psychosocial intervention~8. children in the non-donor group will be matched by age and gender to donor group participants~Exclusion Criteria:~1. participation is limited to one donor per family~2. if a child had matched and declined to donate, that child would not be eligible to participate in the non-donor group

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 19 Years
- Healthy Volunteers: t

Study Arms:
- Anxiety Assessment (Type: None): Minor Donors + Sibling Non-Donors + Parents or Legal Guardians

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of a Prevention Program in Children and Teenagers at High Risk for Bipolar Disorder (Bipokid)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Children and teenagers from 6 to 16 years-old~* At least one biological parent with bipolar disorder~* T-score CBCL-Total ≥ 60~* Written informed consent~Exclusion Criteria:~* Active severe thymic episode~* Autism spectrum disorders~* Intellectual disability

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 16 Years
- Healthy Volunteers: f

Study Arms:
- Family Focused Therapy (Type: OTHER): Only 1 arm

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Exercise and Training on Fat Oxidation During Overfeeding - the FeedEX Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Caucasians~* Male~* Healthy~* 18-30 years~* BMI 21-27.5 kg.m-2~* Sedentary lifestyle: the following serve as (non-strict) guidelines: Low category of activity according to the short version of the International Physical Activity Questionnaire (IPAQ); VO2max (ml.kg-1.min-1) below: 45 - AGE (yrs) / 3 corresponding to a fitness category below fair (i.e. poor or very poor) as defined by Schvartz and Reibold. For example for an 18 year-old male, VO2max below 39 ml.kg-1.min-1.~* Stable body weight (\<5% change in the last 6 months)~Exclusion Criteria:~* Following a (weight-loss) diet~* Using medications~* Smoking~* Consuming more than 3 units of alcohol per day~* Diagnosed with any chronic diseases known to affect energy metabolism (intake/expenditure) such as diabetes, cardiovascular disease, cancer, or thyroid disease.~* Trained or regularly physically active (according to the IPAQ)

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 30 Years
- Healthy Volunteers: t

Study Arms:
- Overfeeding + exercise pre/post training (Type: EXPERIMENTAL): overfeeding + exercise pre-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - before training period.~fitness training: 10-week training period (3 times per week at a gym, 30-45 minutes cardio training and 15-30 minutes strength training).~overfeeding + exercise post-training: day1 energy balance; day2 and day3: energy intake equals 1.25 times day 2 and day 3 energy expenditure respectively, no exercise; day4: 3 cycling bouts to expend 0.25 times day3 energy expenditure + energy intake equals 1.25 times day4 energy expenditure - after training period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy of Losartan on Aortic Dilatation in Patients With Marfan Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 10 years or older~* Marfan syndrome according to international criteria Signed informed consent~Exclusion Criteria:~* Previous surgery of the ascending aorta, or surgery planned~* Non echogenicity~* Contre-indication lactose~* Pregnancy on going or planned within 3 years~* Breast feeding~* Participation in another clinical study~* Non member of the social security or CMU

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A: Placebo (Type: PLACEBO_COMPARATOR): placebo
- B: Losartan (Type: ACTIVE_COMPARATOR): Losartan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Antithrombotic Treatments After Aortic Valve Replacement. Rivaroxaban: A New Antithrombotic Treatment for Patients With Mechanical Prosthetic Aortic Heart Valve.

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients receiving a mechanical aortic valve replacement. This includes also the following combined procedures:~* Coronary artery bypass~* Composite graft~* Coronary re-implantation~* Aortic root, ascending aorta, arch or hemi-arch replacement~* Redo surgery~* Aortic root enlargement~* Three days after end of the primary aortic valve surgery: no mechanical ventilation in the last 12 hours~* Left ventricular ejection fraction \>/=30% preoperative.~* Written informed consent~Exclusion Criteria~* Contraindication to Phenprocoumon or rivaroxaban treatment.~* Premenopausal and fertile women (menopause defined as 1 year free of period)~* Mitral valve surgery~* Aneurysmectomy~* Maze ablation~* Peripheral vascular surgery~* Aortic type A or B dissection~* Patients following mitral valve replacement~* Patients in need of platelets inhibitors other than Aspirin.~* Active infective endocarditis~* Preoperative atrial fibrillation~* Myocardial infarction or percutaneous coronary intervention within 6 months prior to start of rivaroxaban~* Stroke within 6 months prior to start of rivaroxaban~* Systemic embolism within 6 months prior to start of rivaroxaban~* Severe renal impairment (estimated creatinine clearance ≤30 mL/min)~* Conditions associated with an increased risk of bleeding within 6 months prior to start of rivaroxaban:~* Active liver disease, including but not limited to~* Anemia (hemoglobin level \<85g/L) or thrombocytopenia (platelet count \<100 × 109/L)~* Women who are pregnant or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study~* Patients considered unreliable by the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): CATHAR is a prospective, open-label, pilot, phase 2 study with independent evaluation of all outcomes. The trial is based on a Bayesian design by incorporating historical information for the control group for all analyses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Use of Rotational Thromboelastometry (ROTEM) to Characterize Coagulation Abnormalities in Burn Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Consecutive patients admitted to NYPH with 15% TBSA burn or greater.~2. Patients with vascular access catheters (arterial or central line) placed within 24 hours of burn injury~3. Males and females~4. Ages \>3 years or \>15 kg~5. Informed verbal consent obtained from the patient or the patient's designated health care proxy (DHCP). In the case of minors, assent and informed verbal consent obtained from at least one parent or guardian.~Exclusion Criteria:~1. Known pre-existing hemostatic abnormalities~2. Ages \< 3 years or weight \< 15 kg~3. Intake of anticoagulants or antiplatelet aggregation inhibitors prior to burn~4. Pregnant patients~5. Patients with delayed presentation (greater than 24 hours after burn injury)~6. Inclusion in another clinical research study~7. Refusal or inability of patient or patient's DHCP to consent in English.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- ROTEM (Type: EXPERIMENTAL): Clinical burn ICU Inpatients receiving blood draws for ROTEM analysis and fibrinogen levels.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Stereotactic Image Guidance on the Lateral Skull Base

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients which are regularly scheduled for an otologic surgical procedure~* Informed Consent as documented by signature~* Age \>= 18 years~Exclusion Criteria:~* Other clinically condition or disease that would (as deemed by the operating surgeon) significantly increase the risk of surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Navigated (Type: EXPERIMENTAL): Lateral skull base navigation intervention is applied

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Normal Range of Urinary Sodium Levels in Healthy Newborn Babies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria~* Term (37-41 week gestation) infant~* Born at specified maternity unit within study period~* Uncomplicated pregnancy with no antenatal diagnosis~* Uncomplicated postnatal period: no admission to neonatal/special care unit~* Full enteral milk feeds since birth~Exclusion criteria~* \< 37/40 gestation or \> 41/40 gestation infants~* Antenatal diagnosis of congenital abnormality~* Postnatal admission to the neonatal unit/special care baby unit~* Period of total parenteral nutrition

- Gender: ALL
- Minimum Age: None
- Maximum Age: 7 Days
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Seton or Glue for Trans-sphincteric Anal Fistulas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* medium or high trans-sphincteric fistulas of cryptoglandular origin, no previous treatments~Exclusion Criteria:~* Crohn's disease~* anal abscesses~* complex fistulas (horse-shoe type or multiple secondary tracts)~* immunosuppression~* diabetes,~* anal fissures~* pregnancy~* anti-coagulant treatments,~* any allergic reaction to the bioglue components.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- glue (Tissucol ) treatment (Type: EXPERIMENTAL): patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before
- Seton treatment (Type: ACTIVE_COMPARATOR): patients with transsphincteric anal fistulas of cryptoglandular origin never operated on before

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Prostate cancer proven by histopathology~2. Unresectable metastases~3. Progressive disease, both docetaxel naive and docetaxel treated.~4. Castration resistant disease with confirmed testosterone level ≤50 ng/ml under prior androgen deprivation therapy (ADT)~5. Positive 68Ga-PSMA-11 PET/CT (positron emission computed tomography ) or diagnostic 177Lu-PSMA-617 scintigraphy~6. ECOG 0-2~7. Sufficient bone marrow capacity as defined by WBC (white blood cell ) ≥2.500/μl, PLT (platelet) count ≥100.000/μl, Hb≥9.9 g/dl and ANC≥1500 mm3 for the first cycle and WBC≥2.000/ μl,PLT count ≥75.000/μl, Hb≥8.9 g/dl and ANC≥1000 mm3 for the subsequent cycles~8. Signing of the Informed Consent Form~9. Patients enrolling in this trail should have received either Enzalutamide or Abiraterone~Exclusion Criteria:~1. Less than 6 weeks since last myelosuppressive therapy (including Docetaxel, Cabazitaxel, 223Ra, 153Sm) or other radionuclide therapy.~2. Glomerular Filtration Rate (GFR) \<40 ml/min~3. Serum creatinine \> 1.5 ULN~4. AST and ALT\>5xULN~5. Urinary tract obstruction or marked hydronephrosis~6. Diffuse bone marrow involvement confirmed by super-scans

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 177Lu-PSMA-617 (6.0 GBq) (Type: EXPERIMENTAL): Repeated i.v. application of 6.0 GBq (gigabequerel)(+/- 10%, arm 1) every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry
- 177Lu-PSMA-617 (7.4 GBq) (Type: EXPERIMENTAL): Repeated i.v. application of 7.4 GBq (gigabequerel)(+/- 10%, arm 2) of drug every 8+/- 1 weeks; RLT until reaching four cycles or threshold maximum dose to the kidneys of 23 Gy as determined by dosimetry

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men or women at least 18 years of age~2. Prediabetes by ADA criteria (fasting glucose 100-125mg/dl, or HbA1C 5.7-6.4%)~3. Stable coronary artery disease~4. Global myocardial perfusion reserve (MPR) index \< 2.0~5. The patient or guardian agrees to the study protocol and the schedule of clinical and dynamic SPECT follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.~Exclusion Criteria:~1. Contraindications to dapagliflozin~2. Significant renal disease manifested by eGFR\<30 ml/min/1.73m²~3. Unstable or rapidly progressing renal disease~4. Acute coronary syndrome, or any other major cardiovascular events within the previous 6 months~5. Stent placement, or coronary artery bypass graft surgery within the previous 6 months~6. Planned revascularization within 6 months~7. Significant disease (diameter stenosis \>70% by coronary CT angiography) in major epicardial coronary arteries~8. Heart failure requiring loop diuretics~9. Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation (ALT or AST \> 3 times upper limit of normal).~10. Contraindication to adenosine stress test~11. Current treatment for the active cancer~12. Women of child bearing potential who are not willing to use a medically accepted method of contraception. Patient's pregnancy confirmed by positive pregnancy test, or breast-feeding.~13. Expected life expectancy \< 1 year~14. Any clinically significant abnormality identified at the screening visit, physical examination, laboratory tests which, in the judgment of the investigator, would preclude safe completion of the study.~15. Unwillingness or inability to comply with the procedures described in this protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): None
- Lifestyle modification (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Continuous ESP Catheters on Recovery, Pain and Opioid Consumption After Multilevel Spine Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-80~* Presenting for elective multilevel (\>2 spinal levels) spinal fusion~* Lumbar, thoracic, and thoracolumbar procedures included~* Posterior surgical approach~* Willing and able to follow the study protocol~* Able to provide informed consent~Exclusion Criteria:~* Opioid tolerance (more than 60 morphine milliequivalents daily for more than 3 months)~* Daily gabapentin/pregabalin use for longer than 3 months~* Prior spine surgery at the index level~* Allergy or contraindication (including renal, liver disease) to included study medications~* Patient refusal

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- ESP Catheters with Ropivacaine 0.2% (Type: EXPERIMENTAL): None
- ESP Catheters with Saline Solution (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Arsenic Trioxide in Treating Patients With Relapsed or Refractory Hodgkin's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically confirmed relapsed or refractory Hodgkin's disease Relapsed after prior first line treatment with at least 2 regimens, such as: Mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) MOPP/ABV Stanford 5 OR Refractory to a second line regimen, such as: Mesna, ifosfamide, mitoxantrone, and etoposide (MINE) Etoposide, methylprednisolone, high dose cytarabine, and cisplatin (ESHAP) High dose chemotherapy and autologous or allogeneic stem cell transplantation At least 1 measurable lesion~PATIENT CHARACTERISTICS: Age: 16 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Unless documented bone marrow involvement: WBC at least 4,000/mm3 Platelet count at least 100,000/mm3 Hepatic: Bilirubin no greater than 2.0 mg/dL Renal: Creatinine no greater than 2.0 mg/dL Other: Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception HIV negative No other prior malignancies within the past 5 years except curatively treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix No concurrent active infection requiring antibiotics~PRIOR CONCURRENT THERAPY: Biologic therapy: See Disease Characteristics No concurrent biologic agents No concurrent monoclonal antibodies No concurrent bone marrow transplantation Chemotherapy: See Disease Characteristics No other concurrent chemotherapy Endocrine therapy: Not specified Radiotherapy: No concurrent radiotherapy Surgery: Not specified Other: No other concurrent anticancer agents

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues